FDA Approves OXYCODONE AND ACETAMINOPHEN — Eywa Pharma Inc

Eywa Pharma Inc. has received final FDA approval for its ANDA 207510, allowing for the generic sale of the opioid combination oxycodone and acetaminophen by March 21, 2018. The inclusion of this widely distributed pain reliever in the company’s portfolio is expected to immediately impact market dynamics, intensifying price pressure on existing branded and generic competitors in the acute pain segment.